{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=67",
    "query": {
      "condition": "Advanced Stage Solid Tumors",
      "page": 67
    },
    "page_size": 10
  },
  "pagination": {
    "page": 67,
    "page_size": 10,
    "total_count": 3086,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=68&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=66&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:25:16.469Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03099161",
      "title": "Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "preladenant",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-06-27",
      "completion_date": "2018-02-21",
      "has_results": true,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099161"
    },
    {
      "nct_id": "NCT00730470",
      "title": "Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "U3-1287 (AMG888)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U3 Pharma GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2008-08",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2010-07-29",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730470"
    },
    {
      "nct_id": "NCT04849273",
      "title": "A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "ALK Gene Mutation"
      ],
      "interventions": [
        {
          "name": "TPX-0131",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Turning Point Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2021-07-28",
      "completion_date": "2023-04-18",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 7,
      "location_summary": "Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849273"
    },
    {
      "nct_id": "NCT05101356",
      "title": "A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Adenocarcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Metastatic Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Adenocarcinoma",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Antineoplastic Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2021-01-13",
      "completion_date": "2034-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05101356"
    },
    {
      "nct_id": "NCT00519662",
      "title": "Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SNS-314",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sunesis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-08",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Stanford, California • Albuquerque, New Mexico + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00519662"
    },
    {
      "nct_id": "NCT00739453",
      "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "OSI-906",
          "type": "DRUG"
        },
        {
          "name": "erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2008-10-23",
      "completion_date": "2012-03-03",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00739453"
    },
    {
      "nct_id": "NCT00996892",
      "title": "Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Pictilisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2009-11",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-12-30",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00996892"
    },
    {
      "nct_id": "NCT04892017",
      "title": "Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Inlexisertib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Sotorasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Deciphera Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2021-06-15",
      "completion_date": "2026-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 10,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04892017"
    },
    {
      "nct_id": "NCT04802174",
      "title": "Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SCLC",
        "Small Cell Cancer",
        "Advanced Solid Tumor",
        "High Grade Neuroendocrine Cancers"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Berzosertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2021-06-01",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04802174"
    },
    {
      "nct_id": "NCT05025085",
      "title": "A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "AGEN1777",
          "type": "DRUG"
        },
        {
          "name": "a PD-1 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-10-04",
      "completion_date": "2024-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-11-19T08:25:16.469Z",
      "location_count": 11,
      "location_summary": "Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05025085"
    }
  ]
}